Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Kailera's oral GLP-1 asset achieved its goals in Chinese phase 3 obesity and diabetes trials, demonstrating an 11% weight loss. However, the drug experienced high rates of nausea and other side effects.
Coverage from Reuters, Endpoints News, BioPharma Dive, and Fierce Biotech emphasizes that while the pill showed encouraging efficacy, the side effect profile caused Kailera's shares to tumble. Investor's Business Daily reports that this setback coincided with an increase in Eli Lilly's market capitalization.
Future developments depend on how Kailera addresses the high side effect rates reported in the late-stage trials.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 18h ago.
Quick answers
What were the results of Kailera's late-stage trials in China?
The oral GLP-1 asset hit its goals, with reports of 11% weight loss.
Why did Kailera's shares decline despite the drug's efficacy?
Shares tumbled due to high rates of nausea and other side effects observed during the trials.
How did this news affect Eli Lilly?
According to Investor's Business Daily, Eli Lilly's market cap increased following the setback.
Coverage (9)
- Kailera weight loss pill trial results: nausea sinks stock qz.com · 22h ago
- Kailera Therapeutics Announces Positive Topline Data from GlobeNewswire · 22h ago
- Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending BioSpace · 22h ago
- Kailera's GLP-1 drug meets main goal of late-stage trials Yahoo Finance · 22h ago
- Kailera says obesity pill succeeds in late-stage trial in China BioPharma Dive · 22h ago
- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials Endpoints News · 22h ago
- Kailera shares tumble on high nausea rates despite weight-loss drug's success Reuters · 22h ago
- Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials Fierce Biotech · 22h ago
- Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback Investor's Business Daily · 22h ago broke it first
People, places & organizations
Topics
Related trends
New Jurassic Fossil Reveals How Birds Lost Their Dinosaur Tails
A 149-million-year-old fossil from China provides a missing link in understanding how modern birds evolved from long-tailed dinosaurs.
Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs
Employers are resisting the expansion of insurance coverage for high-cost GLP-1 obesity medications.
Big Market Rotation Sends Korean Stocks Tumbling, China Surging
A sharp shift in capital is driving Korean stocks lower while Chinese markets surge, fueled by foreign selling in South Korean chip sectors.
'The water just came so fast': Typhoon triggers floods and rare tornadoes in China
A typhoon has triggered deadly floods and rare tornadoes across several Chinese provinces.
Nestlé to Tweak Some Food Recipes to Appeal to Duller GLP-1 Palates
Nestlé is adjusting food recipes to target the altered taste preferences of consumers using GLP-1 weight-loss medications.
11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy
GLP-1 weight loss drug usage has reached record highs in the United States, with 11% of Americans now using medications like Wegovy.